We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Next Generation Single Molecule Imaging to Transform In Vitro Diagnosis

By LabMedica International staff writers
Posted on 15 Jun 2023

A groundbreaking multi-omic platform designed for in vitro diagnosis can rapidly detect disease biomarkers, leading to earlier diagnoses for a variety of life-threatening illnesses. More...

The state-of-the-art platform is based on SMi Systems’ (Cambridge, UK) advanced super-resolution optical technology that boasts unrivaled spatial (1.6 nanometres) and temporal (0.5 milliseconds) resolution. SMi’s automated, high-precision optical technology provides the capability to view single molecule interactions in real-time. SMi is leveraging this huge leap in optical technology to develop a diagnostic device that can identify single molecules associated with both infectious and non-infectious diseases. When paired with AI, the platform offers unparalleled quantification of disease-associated single molecules. Furthermore, its capacity to simultaneously differentiate between various diseases from a single sample and process hundreds of samples in mere minutes makes it a highly efficient diagnostic tool. SMi has developed proof-of-principle instruments and also demonstrated their effectiveness in detecting infectious diseases.

Single molecule resolution enables diseases to be detected much earlier. The resolution levels offered by SMi's technology are unprecedented and can be tailored to any molecular target, allowing individual particles to be visualized and counted directly for the first time. This offers clinicians undeniable proof of the existence of molecules associated with either infectious or non-infectious diseases. The fully automated system requires less than a second per sample to provide a diagnosis, marking a considerable improvement over less precise lateral flow tests and PCR tests that can take several minutes or even hours. With the ability to process up to 384 samples in just a few minutes, this technology could become a game-changer, particularly for large-scale patient sample screenings in healthcare settings.

“We’ve proved the success of our new platform in both respiratory diseases and cancer biomarker diagnosis, but we’re only just scratching the surface of what is possible using our single molecule imaging technology,” said Dr Andrew Thompson, Chief Executive Officer (CEO) at SMi.

Related Links:
SMi Systems 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.